Ribo Biotech
Suzhou
About Ribo Biotech
Ribo Biotech develops RNA interference drugs and is committed to the research and development of small nucleic acid drugs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $40.0M
- Funding stage: Late Stage Venture
- Last round: Series E (Jul 2022)
- Website: ribolia.com
Industries & Categories
Manufacturing, Medical
Canonical: https://fsome.com/organization/ribo-biotech-123721 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.